SpecificiT Pharma snags seed funding
Montreal-based SpecificiT Pharma Inc, a developer of personalized hematological cancer immunotherapies, has secured an undisclosed amount of seed funding. The investors were AmorChem, Sanderling Ventures and Accel-Rx Health Sciences Accelerator. In addition to the funding, Dr. Pierre Beauparlant, a venture partner at Sanderling Ventures, will become CEO of SpecificiT.
11 September 2017•1 min read
